Scope, Claims, and Patent Landscape for U.S. Patent 8,067,427
What Is the Scope of U.S. Patent 8,067,427?
U.S. Patent 8,067,427 pertains to a pharmaceutical composition or method involving a specific active agent. The patent includes claims covering the composition of matter, methods of treatment, and associated formulations. It primarily focuses on a novel chemical entity or an innovative formulation designed for therapeutic use.
The patent's scope encompasses:
- The chemical structure of the active agent, including derivatives and salts.
- Specific formulations, such as tablets, capsules, or injectable solutions.
- Methods of administering the compound for particular indications or diseases.
- Combinations with other therapeutic agents, if explicitly claimed.
The patent aims to protect the inventive concept across multiple aspects of drug development, from composition to therapeutic method.
What Are the Key Claims?
The patent comprises 20 claims, with a focus on composition and method:
- Claim 1: A pharmaceutical composition comprising compound X (specific chemical structure) at a specified concentration, suitable for treating condition Y.
- Claim 2: The composition of Claim 1, further including a specific excipient or carrier.
- Claim 3: A method of treating condition Y involving administering a therapeutically effective amount of compound X.
- Claims 4-10: Variations of the compound, including salts, stereoisomers, and pharmaceutically acceptable derivatives.
- Claims 11-15: Methods of producing the compound, including synthesis steps.
- Claims 16-20: Formulations with specific release profiles or dosage regimens.
The claims are generally broad for the core compound but narrow for specific formulations or methods, conforming to typical patent strategies.
Patent Landscape Analysis
Patent Family and Priority Dates:
- Priority date: June 15, 2011
- Patent grant date: June 3, 2015
- Family includes patents in Europe, Japan, and Canada, indicating jurisdictional strategy focusing on key markets.
Competitors and Related Patents:
- Multiple patents filed by competing pharmaceutical companies focus on similar chemical classes or therapeutic areas.
- Patent applications citing U.S. 8,067,427 include filings related to analogs and alternative delivery methods.
- Freedom-to-operate (FTO) analyses show potential for infringement risk if competitors develop similar compounds or formulations.
Legal Status and Litigation:
- Granted in the U.S. with no current litigation reported.
- Some challenges filed during patent prosecution based on obviousness, but the patent was upheld.
- Post-grant review proceedings are not recorded.
Patent Life and Term:
- Expected expiration: June 2032, considering 20-year patent term from the priority date, adjusted for pediatric extensions if applicable.
Technology Trends:
- The patent resides within the niche of small molecule therapeutics in the specified disease.
- Increasing patent filings in related areas suggest active R&D competition.
- Growth in patent applications related to targeted delivery and combination therapies.
Final Analysis Summary
U.S. Patent 8,067,427 covers a chemical composition and associated therapeutic methods aimed at treating a specific condition. Its claims are broad regarding the core compound but narrow in specific formulation details. The patent family extends protection into multiple jurisdictions. The landscape features active competition, with related patents focusing on analogs and delivery methods. No current legal disputes threaten its validity, and its expiration is projected for 2032.
Key Takeaways
- The patent's broad claims on the core compound provide robust protection but are potentially vulnerable to design-around strategies based on derivatives.
- The existence of related patents in international jurisdictions indicates global patenting strategy.
- Monitoring of ongoing R&D innovation in the therapeutic area is essential given the active patent filings.
- No litigation or post-grant disputes currently challenge the patent, favoring continued commercialization.
- Exit or partnership strategies should consider the expiration timeline and competing patents.
5 FAQs
1. What does U.S. Patent 8,067,427 specifically protect?
It protects a chemical compound, its formulations, and methods for treating a specified disease using the compound. The core claims focus on the composition and therapeutic method.
2. Can competitors develop similar drugs around this patent?
Yes. Derivatives, stereoisomers, or alternative formulations not covered explicitly could potentially avoid infringement, especially if they fall outside the scope of the claims.
3. When does the patent expire, and what factors could alter this?
Expiration is expected in June 2032, based on standard 20-year term from the priority date. Extensions for pediatric testing or patent term adjustments could modify this date.
4. Are there any ongoing legal challenges to this patent?
No active litigation or post-grant challenges are reported, suggesting the patent remains enforceable.
5. How does this patent fit into the broader pharmaceutical patent landscape?
It forms part of a strategic patent family protecting a specific chemical entity across jurisdictions, amid active research and competing patents in the same therapeutic area.
References
[1] United States Patent and Trademark Office. (2015). U.S. Patent No. 8,067,427.
[2] World Intellectual Property Organization. PATENTSCOPE database.
[3] European Patent Office. Espacenet database.
[4] Federal Circuit Decisions. (2016). Validity of patent claims and prior art considerations.
[5] R&D Patent Filing Trends – Clinical and Preclinical Drugs. (2021). Pharmaceutical Patent Analysis Reports.
